|
Real world prospective evaluation of clinical outcomes in patients with non-metastatic castrate resistant prostate cancer treated with darolutamide. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
Honoraria - Bayer; Janssen; Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen-Cilag |
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi |
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer |
Research Funding - Genzyme |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - EUSA ESMO congress sponsor |
|
|
No Relationships to Disclose |
|
Kamalram Thippu Jayaprakash |
Honoraria - Janssen Oncology |
Research Funding - Bayer UK; National Institute of Health Research (NIHR) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer UK; Janssen Oncology; Pfizer; Roche; Takeda |
Other Relationship - Clinical Oncology Journal |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Eisai Europe |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen (Inst); Sanofi (Inst) |
|
|
Employment - Corin Group; Philips Healthcare |
Research Funding - Janssen (Inst); Sanofi (Inst) |
|
|
Research Funding - Janssen (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |